INCY Incyte Corp
- Stocks
- Healthcare
- NASDAQ: INCY
Price (delayed)
$105.4
Market cap
$20.69B
P/E Ratio
17.45
Dividend/share
N/A
EPS
$6.04
Enterprise value
$18.27B
Relative Growth:
Rel. Growth:
91
Relative Strength:
Rel. Strength:
85
Relative Valuation:
Rel. Valuation:
85
Relative Profitability:
Rel. Profitability:
99
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug,
Highlights
INCY's P/E is 90% below its last 4 quarters average of 167.5 and 79% below its 5-year quarterly average of 85.3
The company's quick ratio has surged by 69% YoY and by 12% QoQ
The debt is up by 10% year-on-year but it is down by 2.4% since the previous quarter
Key stats
What are the main financial stats of INCY
Market
Valuations
Earnings
Shares outstanding
196.32M
Market cap
$20.69B
Enterprise value
$18.27B
Price to earnings (P/E)
17.45
Price to book (P/B)
4.43
Price to sales (P/S)
4.28
PEG
0.01
EV/EBIT
11.49
EV/EBITDA
10.86
EV/Sales
3.8
Revenue
$4.81B
Gross profit
$4.47B
Operating income
$1.48B
Net income
$1.19B
EBIT
$1.59B
EBITDA
$1.68B
Free cash flow
$1.2B
Per share
Balance sheet
Liquidity
EPS
$6.04
EPS diluted
$5.9
Free cash flow per share
$6.12
Book value per share
$23.82
Revenue per share
$24.6
TBVPS
$30.95
Total assets
$6.33B
Total liabilities
$1.68B
Debt
$35.37M
Equity
$4.65B
Working capital
$2.94B
Debt to equity
0.01
Current ratio
3.2
Quick ratio
2.86
Net debt/EBITDA
-1.44
Margins
Efficiency
Dividend
EBITDA margin
35%
Gross margin
92.9%
Net margin
24.7%
Operating margin
30.8%
Return on assets
20.4%
Return on equity
29.8%
Return on invested capital
76%
Return on capital employed
31.9%
Return on sales
33%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INCY stock price
How has the Incyte stock price performed over time
Intraday
-0.28%
1 week
13.84%
1 month
20.83%
1 year
30.2%
YTD
52.6%
QTD
24.28%
Financial performance
How have Incyte's revenue and profit performed over time
Revenue
$4.81B
Gross profit
$4.47B
Operating income
$1.48B
Net income
$1.19B
Gross margin
92.9%
Net margin
24.7%
INCY's net income is up by 36% since the previous quarter
The net margin is up by 30% since the previous quarter
Incyte's operating income has increased by 25% from the previous quarter
INCY's operating margin is up by 19% since the previous quarter
Price vs fundamentals
How does INCY's price correlate with its fundamentals
Growth
What is Incyte's growth rate over time
Valuation
What is Incyte stock price valuation
P/E
17.45
P/B
4.43
P/S
4.28
EV/EBIT
11.49
EV/EBITDA
10.86
EV/Sales
3.8
INCY's P/E is 90% below its last 4 quarters average of 167.5 and 79% below its 5-year quarterly average of 85.3
INCY's EPS is up by 37% QoQ
INCY's equity is up by 47% year-on-year and by 12% since the previous quarter
The stock's price to book (P/B) is 31% more than its last 4 quarters average of 3.4 and 8% more than its 5-year quarterly average of 4.1
INCY's P/S is 39% above its last 4 quarters average of 3.1 but 4.4% below its 5-year quarterly average of 4.5
Incyte's revenue has increased by 18% YoY and by 5% from the previous quarter
Efficiency
How efficient is Incyte business performance
INCY's return on assets is up by 29% since the previous quarter
The ROE has grown by 24% from the previous quarter
The ROIC has increased by 21% from the previous quarter
INCY's ROS is up by 20% QoQ
Dividends
What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INCY.
Financial health
How did Incyte financials performed over time
The current ratio has soared by 71% YoY and by 12% from the previous quarter
The company's quick ratio has surged by 69% YoY and by 12% QoQ
The debt is 99% smaller than the equity
INCY's equity is up by 47% year-on-year and by 12% since the previous quarter
The debt is up by 10% year-on-year but it is down by 2.4% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.